Please assess the completion status of the following clinical trial:

Trial Title: Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who understand and sign the informed consent form voluntarily.~2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex.~3. hospitalized patients diagnosed with acute coronary syndrome within 1 month.~4. at least one non-culprit lesion with diameter stenosis percentage of 30% to 70% by visual estimation on coronary angiography (CAG) after completing any planned percutaneous revascularization.~5. the lesion shown by OCT was lipid-rich plaque (Lipid pool arc \> 90 °).~Exclusion Criteria:~1. Allergic to colchicine.~2. Colchicine was taken within 10 days before randomization.~3. Abnormal liver function (ALT \> 3 times the upper limit of normal value).~4. Abnormal renal function (creatinine clearance rate \< 45 ml/min).~5. Thrombocytopenia (PLT \< 100G/L).~6. Uncontrolled infectious diseases during the screening period.~7. Known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on.~8. Pre-existing or plan for the administration of systemic anti-inflammatory treatments such as non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs.~9. History of surgery or interventional therapy within 6 months prior to the screening period.~10. A history of coronary artery bypass grafting or a plan for coronary artery bypass grafting within 1 year.~11. Left main coronary disease (≥50% reduction in lumen diameter by angiographic visual estimation).~12. Significant coronary calcification or tortuosity deemed to preclude OCT evaluation.~13. Diagnosed with mental disorders such as anxiety or depression.~14. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive methods.~15. Participated in other clinical trials within 3 months before the screening period.~16. Do not receive standardized treatment after being diagnosed with coronary heart disease.~17. The life expectancy of the subjects is less than 1 year.~18. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): colchicine (0.5mg), one pill a day, oral intake
- Control Group (Type: PLACEBO_COMPARATOR): placebo, one pill a day, oral intake

Based on this trial design, predict the completion outcome and termination type (if applicable).